JP2002525329A5 - - Google Patents

Download PDF

Info

Publication number
JP2002525329A5
JP2002525329A5 JP2000571925A JP2000571925A JP2002525329A5 JP 2002525329 A5 JP2002525329 A5 JP 2002525329A5 JP 2000571925 A JP2000571925 A JP 2000571925A JP 2000571925 A JP2000571925 A JP 2000571925A JP 2002525329 A5 JP2002525329 A5 JP 2002525329A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
drug
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000571925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/021780 external-priority patent/WO2000018407A1/en
Publication of JP2002525329A publication Critical patent/JP2002525329A/ja
Publication of JP2002525329A5 publication Critical patent/JP2002525329A5/ja
Pending legal-status Critical Current

Links

JP2000571925A 1998-09-25 1999-09-24 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法 Pending JP2002525329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10176398P 1998-09-25 1998-09-25
US60/101,763 1998-09-25
PCT/US1999/021780 WO2000018407A1 (en) 1998-09-25 1999-09-24 Methods for preventing/treating damage to sensory hair cells and cochlear neurons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011014273A Division JP5190125B2 (ja) 1998-09-25 2011-01-26 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法

Publications (2)

Publication Number Publication Date
JP2002525329A JP2002525329A (ja) 2002-08-13
JP2002525329A5 true JP2002525329A5 (cg-RX-API-DMAC7.html) 2006-11-24

Family

ID=22286288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000571925A Pending JP2002525329A (ja) 1998-09-25 1999-09-24 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法
JP2011014273A Expired - Fee Related JP5190125B2 (ja) 1998-09-25 2011-01-26 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011014273A Expired - Fee Related JP5190125B2 (ja) 1998-09-25 2011-01-26 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する/処置するための方法

Country Status (13)

Country Link
US (2) US6448283B1 (cg-RX-API-DMAC7.html)
EP (1) EP1126855B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002525329A (cg-RX-API-DMAC7.html)
KR (1) KR100628847B1 (cg-RX-API-DMAC7.html)
CN (1) CN1329034C (cg-RX-API-DMAC7.html)
AT (1) ATE361752T1 (cg-RX-API-DMAC7.html)
AU (1) AU763435B2 (cg-RX-API-DMAC7.html)
CA (1) CA2345295C (cg-RX-API-DMAC7.html)
DE (1) DE69936059T2 (cg-RX-API-DMAC7.html)
ES (1) ES2288042T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040053B (cg-RX-API-DMAC7.html)
NZ (1) NZ511024A (cg-RX-API-DMAC7.html)
WO (1) WO2000018407A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP4623962B2 (ja) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US7390797B2 (en) 2002-02-28 2008-06-24 Eisai Co., Ltd. Fused indazole compounds
BR0314561A (pt) * 2002-10-10 2006-01-17 Uab Research Foundation Sistema e método de neuro-proteção ativa para detectar e impedir ferimento traumático do cérebro e ferimento da medula espinhal
WO2005122887A2 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Adpll回路、半導体装置及び携帯情報機器
DE102010007281A1 (de) * 2010-02-08 2011-08-11 EMC microcollections GmbH, 72070 Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
AU3064992A (en) * 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994027982A1 (en) 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
US5929041A (en) 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
AU721942B2 (en) 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
AU758241B2 (en) 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles

Similar Documents

Publication Publication Date Title
RU2204561C2 (ru) Производные ксантина с концевыми аминированными алкинольными боковыми цепями и лекарственное средство
JP2001525359A5 (cg-RX-API-DMAC7.html)
JP2022520061A5 (cg-RX-API-DMAC7.html)
CA2345295A1 (en) Use of fused pyrrolocarbazoles in preventing/treating damage to sensory hair cells and cochlear neurons
JP2005526107A5 (cg-RX-API-DMAC7.html)
JP2004509900A5 (cg-RX-API-DMAC7.html)
CA2430692A1 (en) Geldanamycin derivative and use of same to treat cancer
JP2002501049A5 (cg-RX-API-DMAC7.html)
JP2001526218A5 (cg-RX-API-DMAC7.html)
JP2003509349A5 (cg-RX-API-DMAC7.html)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
RU96109699A (ru) Гуанидиды алкенилкарбоновых кислот, способ их получения, содержащее их лекарственное или диагностическое средство, способ его получения, способ лечения и профилактики сердечных заболеваний
KR890006228A (ko) 항종양제로서 폴리아민 유도체
HUP0103303A2 (hu) Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US6576612B1 (en) Antitumor therapy comprising distamycin derivatives
CA2373634A1 (en) Isophosphoramide mustard analogs and use thereof
RU96103685A (ru) 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция
AU2002221622A1 (en) Antitumor therapy comprising distamycin derivatives
JP2003535890A5 (cg-RX-API-DMAC7.html)
JP2003535890A (ja) アクリロイルジスタマイシン誘導体並びにトポイソメラーゼi及びii阻害剤を含む薬剤組成物
RU99122032A (ru) Производные доластатина-15 в комбинации с таксанами
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
CA2410160C (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤